

**GLOBAL CARE CAPITAL INC.
(FORMERLY RESINCO CAPITAL PARTNERS INC.)**

MANAGEMENT DISCUSSION AND ANALYSIS – QUARTERLY HIGHLIGHTS

FOR THE THREE MONTHS ENDED

MARCH 31, 2021 AND 2020

(EXPRESSED IN CANADIAN DOLLARS)

**GLOBAL CARE CAPITAL INC.
(FORMERLY RESINCO CAPITAL PARTNERS INC.)
MANAGEMENT’S DISCUSSION AND ANALYSIS – QUARTERLY HIGHLIGHTS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020**

INTRODUCTION

The following management discussion and analysis – quarterly highlights (“MD&A – Quarterly Highlights”) of the results of operations and financial condition of Global Care Capital Inc. (formerly Resinco Capital Partners Inc.) (“Global” or the “Company”) for the three months ended March 31, 2021 and up to the date of this MD&A – Quarterly Highlights, has been prepared to provide material updates to the business operations, financial condition, liquidity and capital resources of the Company since its last management discussion and analysis for the year ended December 31, 2020 (the “Annual MD&A”)

This MD&A – Quarterly Highlights should be read in conjunction with the Annual MD&A and the audited financial statements for the year ended December 31, 2020, together with the notes thereto, and the accompanying unaudited condensed interim financial statements and related notes thereto for the three months ended March 31, 2021

All financial information in this MD&A – Quarterly Highlights is derived from the Company’s financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) and all dollar amounts are expressed in Canadian dollars unless otherwise indicated.

The effective date of this MD&A – Quarterly Highlights is May 28, 2021.

DESCRIPTION OF BUSINESS

Global was incorporated under the laws of British Columbia on May 25, 2004. The Company’s shares are listed for trading on the Canadian Securities Exchange (“CSE”) under the ticker symbol “HLTH”, the Frankfurt Stock Exchange under the symbol L6V1.F and on the United States OTC stock market’s OTC Pink, under the symbol RSCZF. The registered office of the Company is Suite 810 – 789 West Pender Street, Vancouver, British Columbia, Canada, V6C 1H2.

Global is a global investment company which specializes in providing early-stage financing to private and public companies in the medical marijuana, pharmaceutical, technology, and mining sectors. The Company engages in new, early-stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early-stage investment opportunities that adequately reflect the risk profile.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. The impact on the Company is not currently determinable but management continues to monitor the situation.

OPERATIONAL HIGHLIGHTS

Investments

Healthview Technologies Inc.

Healthview provides wellness support and mental health solutions and services to both employers and employees. HealthView’s Telehealth App provides a comprehensive platform for businesses to scale a virtual care program. Healthcare practitioners are able to expand the reach of their practice and automation creates more efficient administrative workflow. This in turn, saves time and increases profitability. The HealthView App lets a patient complete intake forms on any personal electronic device. As the population continues to work remotely and from home mental health and workplace wellness is becoming increasingly in more demand and more important than ever before. HealthView is an online solution and tool that employees and employment firms will be able to use to maintain wellness and provide support for staff.

ViralClear Rapid Test Corp.

ViralClear focuses on commercializing novel products that address significant healthcare needs with a specific target on the novel coronavirus (COVID-19). The company’s main focus is marketing its ViralClear Rapid IgM-IgG Combined Antibody Test and ViralCare PPE. The ViralClear Rapid IgM-IgG Combined Antibody Test for COVID-19 is a lateral flow immunoassay used to qualitatively detect both early and late marker IgG/IgM antibodies. ViralCare is aimed at minimizing at-work risks by supplying PPE for employees and innovative products and devices which monitor potential viral outbreaks.

**GLOBAL CARE CAPITAL INC.
(FORMERLY RESINCO CAPITAL PARTNERS INC.)
MANAGEMENT’S DISCUSSION AND ANALYSIS – QUARTERLY HIGHLIGHTS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020**

OPERATIONAL HIGHLIGHTS (CONTINUED)

Investments (continued)

ASIC Power Company

On January 28, 2021, the Company completed the acquisition of all of the issued and outstanding securities in the capital of ASIC Power Company (“ASIC”). The Company issued an aggregate of 100,000,000 common shares of Global Care (the “Consideration Shares”) to ASIC shareholders at a deemed price of \$0.095 per Consideration Share. There is no hold period for the Consideration Shares pursuant to applicable securities laws.

Stock Options

On February 4, 2021, the Company granted incentive stock options to its directors, officers and consultants to purchase an aggregate of 3,650,000 common shares with an exercise price of \$0.115 per share for up to five (5) years.

Warrants

During the period ended March 31, 2021, the Company issued 10,075,000 common shares for total proceeds of \$515,000 pursuant to warrants exercised.

During the period ended March 31, 2021, the Company issued 250,000 common shares for total proceeds of \$25,000 pursuant to finders’ warrants exercised.

Subsequent Event Highlights

On April 8, 2021, ASIC has entered into its first royalty streaming agreement to finance 208 ASIC miners from MicroBT and equivalents generating 16’640 TH/s. As of May 10, 2021, these miners have been successfully plugged in and installed at the hosting facility. Full mining capacity of the machines is anticipated to be reached by the end of May 2021.

The Company entered into a share exchange agreement dated April 21, 2021 (the “Agreement”) between the Company, CCM Technologies Inc. (“CCM”) and the securityholders of CCM which sets out the terms and conditions for the acquisition by the Company of all of the issued and outstanding securities in the capital of CCM (the “Transaction”). CCM is a cryptocurrency mining company with state-of-the-art ASIC chips.

The material terms of the Transaction are as follows:

- In consideration for the Transaction, the Company will issue 94,170,001 common shares of the Company (the “Consideration Shares”) to CCM shareholders at a deemed price of \$0.11 per Consideration Share and issue to CCM warrant holders an aggregate of 65,000,000 common share purchase warrants (the “Consideration Warrants”)
- Each Consideration Warrant permits the holder thereof to acquire one Global Care common share at a price of \$0.05 until March 1, 2023

KEY INVESTMENT PORTFOLIO DESCRIPTION

Healthview Technologies Inc.

On September 14, 2020, the Company completed the acquisition of all of the issued and outstanding securities in the capital of Healthview Technologies Inc. (“Healthview”) in exchange for securities of Global Care (the “Transaction”). At closing, the Healthview shareholders will receive an aggregate of 20,000,000 common shares and 10,000,000 common share purchase warrants of the Company at an exercise price of \$0.05 until August 27, 2021.

On October 6, 2020, the Company announced its portfolio company, Healthview has launched its new Telehealth App on Apple Store and Google Play.

**GLOBAL CARE CAPITAL INC.
(FORMERLY RESINCO CAPITAL PARTNERS INC.)
MANAGEMENT'S DISCUSSION AND ANALYSIS – QUARTERLY HIGHLIGHTS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020**

KEY INVESTMENT PORTFOLIO DESCRIPTION (CONTINUED)

Healthview Technologies Inc. (continued)

During the period ended March 31, 2021, Healthview achieved its two earn-out milestones by onboarding its first customers across the retail, hospitality, medical, finance and transportation industries to offer Mental Health Services and by generating revenue. As a result, the Company issued 20,000,000 common shares (the "Earn-Out Shares") with a fair value of \$1,700,000. The Earn-Out Shares will not be subject to any hold period under applicable securities laws.

360 Life Sciences Corp.

On August 4, 2020, the Company sold of all of the issued and outstanding shares of its wholly-owned subsidiary ReFormation Pharmaceuticals Corp. ("ReFormation") to 360 Life Sciences Corp. ("360 Life Sciences") in exchange for 800,000 common shares of 360 Life Sciences. pursuant to the share purchase agreement dated June 24, 2020.

ViralClear Rapid Test Corp.

Pursuant to the terms of the Share Purchase Agreement with ViralClear, Global Care Capital issued 24,000,000 common shares of the Company (each a "Consideration Share") to the vendors in return for a 100% interest in ViralClear. At closing, the ViralClear option holders exchanged their outstanding ViralClear options (the "ViralClear Options") for replacement Global Care Capital options (each a "Global Care Capital Option"). Each ViralClear Option was exchanged for a Global Care Capital Option on a 1:1 basis for an aggregate of 2,900,000 Global Care Capital Options. Of the aggregate number of Global Care Capital Options to be issued, 2,400,000 Global Care Capital Options have an exercise price of \$0.50 per Global Care Capital common share until April 15, 2022; and 500,000 Global Care Capital Options have an exercise price of \$0.20 per Global Care Capital common share until April 15, 2022. Upon completion of the transaction, ViralClear became a wholly owned subsidiary of the Company.

As a major investment into the healthcare sector, ViralClear presents a tremendous opportunity. The novel coronavirus has become a worldwide pandemic that requires serious intervention for countries to return to status quo. The Company is not making any express or implied claims that it has the ability to treat the COVID-19 virus at this time. ViralClear is a start-up company in the newly created COVID-19 antibody test market and has commenced sales and distribution of its test kits in Mexico.

As a distributor, ViralClear's focus on commercialization targets the marketing and distribution portion of the value chain. ViralClear's manufacturing partner, Shanghai Liangrun Biomedicine Technology Co., Ltd., has production capacity of one million test kits per week at their factory in Shanghai, China.

On April 20, 2020, ViralClear, obtained Emergency Use Authorization (EUA) by the Food and Drug Administration ("FDA") for the COVID-19 test kits it distributes and markets. ViralClear's tests can be used by clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA). ViralClear's COVID-19 test kit also has CE marking allowing sales to the European Community, and to other global markets that accept a CE marking as valid regulatory approval following routine local product registration.

Global Gaming Technologies Corp.

Global Gaming Technologies Corp. is a gaming industry holding company that provides investment exposure to digital interactive entertainment in emerging technologies, such as Augmented Reality, Virtual Reality, and Artificial Intelligence, in addition to eSports and traditional game platforms, such as mobile and console. It is focused on gamifying content using visual cinematics across all platforms. The Company's strategy is to publish games and content that are immersive in storytelling, bold in design, and technologically innovative. The Company is managed by game and film industry pioneers. It is headquartered in Toronto, Canada with its primary game studio in Los Angeles, California. GGAM is listed on the Canadian Securities Exchange ("CSE") and its common shares trade under the ticker symbol "GGAM.U". On December 31, 2019, the Company impaired its investment in Global to \$Nil due to the fact that Global needs to raise significant money to settle its debt and the uncertainty of its ability to raise these funds in a timely manner, resulting in \$392,544 of impairment expense.

**GLOBAL CARE CAPITAL INC.
(FORMERLY RESINCO CAPITAL PARTNERS INC.)
MANAGEMENT’S DISCUSSION AND ANALYSIS – QUARTERLY HIGHLIGHTS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020**

KEY INVESTMENT PORTFOLIO DESCRIPTION (CONTINUED)

ASIC Power Company

On January 28, 2021, the Company acquired all of the issued and outstanding securities in the capital of ASIC in exchange for 100,000,000 common shares of the Company with a fair value of \$11,500,000 issued to ASIC shareholders. ASIC is a cryptocurrency company combining state of the art ASIC chips with royalty streaming contracts. ASIC gives mining companies access to its innovative cryptocurrency mining streaming contracts and chip pipeline through its partnerships with leading hardware producers. It intends to identify low cost, renewably powered mining operations to implement new financing strategies in the form of royalties and stream contracts globally.

EQUITY TRANSACTIONS

On January 28, 2021, the Company issued 100,000,000 common shares of the Company to ASIC shareholders. On completion of the acquisition of all of the issued and outstanding securities in the capital of ASIC with a fair value of \$11,500,000.

On February 2, 2021, the Company issued 10,000,000 common shares to Healthview with a fair value of \$900,000 in connection in achieving the first earn-out milestone whereby they onboarded their first customers across the retail, hospitality, medical, finance and transportation industries to offer Mental Health Services.

On March 4, 2021, the Company issued 10,000,000 common shares to Healthview with a fair value of \$800,000 in connection with achieving its second and final of two earn-out milestones by generating revenue.

During the period ended March 31, 2021, the Company issued 10,075,000 common shares for total proceeds of \$515,000 pursuant to warrants exercised.

During the period ended March 31, 2021, the Company issued 250,000 common shares for total proceeds of \$25,000 pursuant to the exercise of finder’s warrants exercised. In addition, \$24,394 representing the fair value of the finders’ warrants was re-allocated from share-based payments reserves to share capital.

TRENDS AND INVESTMENT STRATEGY

Global is focused on early-stage investment opportunities in private and public companies. The Company recognizes two enterprise value enhancers; (1) the transition from private to public assets, and; (2) investing in assets which have been overlooked and have not realized their latent potential.

Engagement of this strategy has resulted in increases in the value of the Company’s portfolio historically, however the depressed state of the junior market sector has affected all publicly traded entities over the last several years. All forms of financing continue to be very constrained for early-stage companies and this has resulted in the quantity of financings to be severely reduced and arduous to complete successfully.

Due to the depressed state on the junior markets, the Company reviewed potential opportunities in Block Chain and Technology sector and is now focused on potential investments in the Cannabis Pharmaceutical Sector. In particular, the Company is reviewing early-stage investment opportunities in previously underdeveloped life and sciences and biotech companies with a specific focus on Cannabis Pharma.

The Company evaluates its portfolio on a regular basis and is actively reviewing new opportunities for investment.

**GLOBAL CARE CAPITAL INC.
(FORMERLY RESINCO CAPITAL PARTNERS INC.)
MANAGEMENT'S DISCUSSION AND ANALYSIS – QUARTERLY HIGHLIGHTS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020**

INVESTMENTS SUMMARY

	March 31, 2021		December 31, 2020	
	Cost \$	Fair value \$	Cost \$	Fair value \$
Public Company Investments	988,881	372,018	988,881	223,670
Private Company Investments	64,591,645	11,666,669	53,091,645	166,669
Total	65,580,526	12,038,687	54,080,526	390,339

As at March 31, 2021, the Company held public company investments with a fair value of \$372,018 compared to \$223,670 as at December 31, 2020. This is mainly due to the increase in 180 Life Sciences Corp shares fair value of \$211,230.

As at March 31, 2021, the Company held private company investments with a fair value of \$11,666,669, compared to \$166,669 at December 31, 2020. This increase is due to the Company acquiring all of the issued and outstanding securities in the capital of ASIC in exchange for 100,000,000 common shares of the Company with a fair value of \$11,500,000 issued to ASIC shareholders

RESULTS FROM OPERATIONS

Three-month period ended March 31, 2021 (“2021”) compared to three-month period ended March 31, 2020 (“2020”)

During 2021, the Company incurred a net loss of \$576,989 compared to \$58,376 in 2020.

The key differences in expenses between 2021 and 2020 were as follows:

- Unrealized gains on investment of \$148,347 (2020 \$ 24,817)
- \$169,145 (2020 - \$Nil) in advertising and promotion expense due to the hiring of Aktien, a public relations consultant.
- Share based compensation of \$417,247 (2020 - \$Nil) was recognized on the grant of share options granted to various directors, officers, employees and consultants during the quarter.

SUMMARY OF QUARTERLY RESULTS

	March 31, 2021	December 31, 2020	September 30, 2020	June 30, 2020
Net investment gain (loss)	\$148,347	\$(41,166,136)	\$(1,383,798)	\$440
Loss and comprehensive loss	\$(576,989)	\$(43,524,798)	\$(2,446,321)	\$(7,350,769)
Earnings (loss) per share – basic and diluted	(0.01)	(0.84)	(0.02)	(0.13)

	March 31, 2020	December 31, 2019	September 30, 2019	June 30, 2019
Net investment loss	\$35,665	494,049	\$(20,980)	\$(155,812)
Loss and comprehensive loss	\$(58,376)	(10,874,242)	(136,333)	\$(712,416)
Earnings (loss) per share – basic and diluted	(0.01)	(2.24)	(0.03)	(0.25)

The quarterly financial information for 2021, 2020 and 2019 are presented in accordance with IFRS.

The Company has been negatively affected by poor stock market performance, volatile commodity prices and weakened global economic performance. Due to an investment portfolio which is weighted in early-stage companies, quarter-to-quarter performance is affected by volatility in the stock markets. The amount and timing of expenses and availability of capital resources vary substantially quarter to quarter, depending on the level of investment activities being undertaken at the time.

**GLOBAL CARE CAPITAL INC.
(FORMERLY RESINCO CAPITAL PARTNERS INC.)
MANAGEMENT’S DISCUSSION AND ANALYSIS – QUARTERLY HIGHLIGHTS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020**

LIQUIDITY AND CAPITAL RESOURCES

At March 31, 2021, the Company had cash and cash equivalents of \$505,187 and working capital (deficit) of \$554,181 compared to \$321,608 and \$(1,526,076), respectively as at December 31, 2020. Since the Company’s inception, operations have been financed through the issuance of equity securities and the sale of the Company’s investments.

The Company began the year with cash and cash equivalents of \$321,608. In the period ended March 31, 2021, the Company used net cash of \$856,256 on operating activities and received \$1,039,835 from financing activities related to the exercise of warrants and finder’s warrants and the receipt of proceeds from loans payable during the period.

During the period ended March 31, 2021, the Company limited cash outflow due to operating activities through share-based compensation in the amount of \$417,247. As well, to complete acquisitions, the company incurred transaction costs through the issuance of common shares in the amount of \$13,200,000. Various unrealized gains or losses occurred related to various investments during the period amounting to a gain of \$188,848.

CASH FLOWS – OPERATING ACTIVITIES

Net cash used in operating activities during the period ended March 31, 2021 was \$856,256 (2020 - \$40,453) which mainly consisted of cash spent for general working capital, corporate development, consulting and professional fees for investment opportunities.

CASH FLOWS – FINANCING ACTIVITIES

Total net cash generated during the period ended March 31, 2021 was \$1,039,835 (2020 - \$50,000). During fiscal 2020, \$2,500,000 was received pursuant to private placements and \$125,000 were received pursuant to options exercised. The Company paid \$194,425 in finders’ fee pursuant to the private placements.

CONTRACTUAL OBLIGATIONS

As at March 31, 2021, the Company had no contractual obligations.

OFF-BALANCE SHEET ARRANGEMENTS

The Corporation was not party to any off-balance sheet arrangements as of March 31, 2021.

RELATED PARTY TRANSACTIONS

The Directors and Executive Officers of the Company are as follows:

Alexander Somjen	Director, Chief Executive Officer & President
James Henning	Chief Financial Officer (appointed April 15, 2020)
Theo van der Linde	Former Chief Financial Officer (resigned on January 13, 2020)
Eugene Beukman	Former Corporate Secretary (resigned on January 13, 2020)
Troy Grant	Director
Maciej Lis	Director

The following directors and/or senior officers transacted with the Company in the reporting period. The terms and conditions of the transactions with key management personnel and their related parties were no more favourable than those available, or which might reasonably be expected to be available, on similar transactions to non-key management personnel related entities on an arm’s length basis. The aggregate value of transactions relating to key management personnel were as follows:

**GLOBAL CARE CAPITAL INC.
(FORMERLY RESINCO CAPITAL PARTNERS INC.)
MANAGEMENT’S DISCUSSION AND ANALYSIS – QUARTERLY HIGHLIGHTS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020**

RELATED PARTY TRANSACTIONS (CONTINUED)

	March 31, 2021	March 31, 2020
	\$	\$
Consulting fees paid to a company controlled by the CEO	\$ 33,900	\$ 50,850
Consulting fees paid to the CFO	1,575	-
Consulting fees and rent paid to companies controlled by the former CFO	-	9,975
Share-based compensation	360,090	-
Total	\$ 395,565	\$ 60,825

As at March 31, 2021, there was \$270,100 (December 31, 2020 - \$273,850) due to current and former officers and management of the Company.

On January 17, 2020, the Company entered into a loan agreement in the amount of \$50,000 with a company jointly controlled by the former corporate secretary and CFO. The loan was due on demand and interest accrued on the principal amount at the rate of 8% per annum. On April 9, 2020, the loan was settled with common shares of the Company.

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Financial instruments

The Company’s financial instruments consist of cash and cash equivalents, loans receivable, investments, accounts payable and accrued liabilities and contingent consideration liability. The carrying value of loans receivable and accounts payable and accrued liabilities approximates their fair value due to the short-term nature. Cash and cash equivalents and contingent consideration liability are recorded at fair value using Level 1 of the fair value hierarchy. As at March 31, 20221, investments in public companies of \$412,518 (December 31, 2020 - \$223,670) are recorded at fair value using Level 1 of the fair value hierarchy and investments in private companies of \$11,666,669 (December 31, 2020 - \$166,669) are recorded at fair value using level 2 of the fair value hierarchy.

The Company’s financial instruments recorded at fair value require disclosure about how the fair value was determined based on significant levels of inputs described in the following hierarchy:

- Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions occur in sufficient frequency and value to provide pricing information on an ongoing basis.
- Level 2 - Pricing inputs are other than quoted prices in active markets included in Level 1. Prices in Level 2 are either directly or indirectly observable as of the reporting date. Level 2 valuations are based on inputs including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the marketplace.
- Level 3 - Valuations in this level are those with inputs for the asset or liability that are not based on observable market data.

The following table presents the Company’s financial instruments, measured at fair value on a recurring basis on the statements of financial position and categorized into levels of the fair value hierarchy:

**GLOBAL CARE CAPITAL INC.
(FORMERLY RESINCO CAPITAL PARTNERS INC.)
MANAGEMENT'S DISCUSSION AND ANALYSIS – QUARTERLY HIGHLIGHTS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020**

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONTINUED)

Financial instruments (continued)

	Level 1	Level 2	Level 3	Total
March 31, 2021	\$	\$	\$	\$
Cash and cash equivalents	505,187	-	-	505,187
Investments	372,018	11,666,669	-	12,038,687
December 31, 2020	\$	\$	\$	\$
Cash and cash equivalents	321,608	-	-	321,608
Investments	223,670	166,669	-	390,339
Contingent consideration liability	-	-	1,700,000	1,700,000

There were no transfers between levels during the period.

The following table reconciles the Company's Level 3 fair value investments:

Level 3	Period ended March 31, 2021	Year ended December 31, 2020
	\$	\$
Balance, beginning	-	462,001
Additions	-	40,641,687
Net change in unrealized gain (loss) on investments	-	(41,103,688)
Balance, ending	-	-

Risk management

The Company is or may be subject to certain risks including interest rate risk, currency risk, credit risk and market risk. Risk management strategies may expose the Company to further gains or losses, but serve to stabilize future cash flows, reduce the volatility of operating results and increase overall financial strength.

Currency risk

The Company has foreign investments and is therefore subject to currency risk. Management believes these investment and transaction amounts are not significant and there are no material foreign currency commitments. The currency risk is therefore manageable and not significant. The Company does not currently use any derivative instruments to reduce its exposure to fluctuations in foreign currency exchange rates.

Credit risk

Credit risk is the risk associated with the inability of a third party to fulfil its payment obligations. The Company is exposed to the risk that third parties that owe money or securities in connection with services provided, or for other purposes, will default on their underlying obligations.

Prior to accepting any service engagement or providing any loan, the Company assesses future recoverability by examining the entities' financial conditions, properties and assets, business development activities and management. The Company manages its exposure to credit risk by reviewing the outstanding balances on an ongoing basis, monitoring the amount attributable to each counterparty and the length of time taken for amounts to be settled. Where necessary, management takes appropriate action to follow up on those balances considered overdue.

**GLOBAL CARE CAPITAL INC.
(FORMERLY RESINCO CAPITAL PARTNERS INC.)
MANAGEMENT'S DISCUSSION AND ANALYSIS – QUARTERLY HIGHLIGHTS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020**

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONTINUED)

Risk management (continued)

Liquidity risk

Liquidity risk is the risk that the Company will have insufficient cash resources to meet its financial obligations as they become due. The Company's liquidity and operating results may be adversely affected if the Company does not have access to the capital markets, whether as a result of a downturn in general market conditions or related to matters specific to the Company, or if the value of the Company's investments decline, resulting in lower proceeds and/or losses on disposition. The Company generates cash flows primarily from the disposition of its investments and from its financing activities.

The Company's investments focus on early-stage companies which can at times be relatively illiquid and if the Company decides to dispose of certain securities, it may not be able to do so at favorable prices at that time, or at all. However, the Company has sufficient marketable securities which are freely tradable and relatively liquid to fund its obligations as they become due under normal operating conditions such that, in the absence of overall market disruptions or exceptional circumstances, liquidity risk can be minimized.

The Company expects accounts payable and accrued liabilities and contingent consideration liabilities to be settled within 12 months of March 31, 2021.

Market risk

Market risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in market prices. The value of the financial instruments can be affected by changes in interest rates, foreign exchange rates and equity and commodity prices. The Company is exposed to market risk in trading its investments and unfavourable market conditions could result in dispositions of investments at less than favourable prices. The Company's investments are primarily concentrated in early-stage companies, which results in exposure to higher volatility than broader market investments and indexes. The Company's investments are accounted for at fair value and are sensitive to changes in market bid prices, such that changes in market prices result in a proportionate change in the carrying value of the Company's investments. A 10% change in the fair values of the Company's investments at March 31, 2021 would have a \$1,203,687 (2020 - \$48,000) impact on operations.

Concentration risk

The Company is subject to concentration risk due to the nature of the Company's operations as an investment company and the number of investments held in the portfolio which consists primarily of early-stage companies and their related technologies. As a result, the investment portfolio is directly exposed to the risks associated with companies operating in these industry sectors.

As at March 31, 2021, approximately 99.6% (December 31, 2020 - 82%) of the fair value of the Company's investment portfolio consisted of investments in three (December 31, 2020 - two) companies with the largest single investment comprising 95% (December 31, 2020 - 43%) of the total portfolio value.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

Statements in this MD&A – Highlights other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, constitute forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, among others, statements pertaining to:

**GLOBAL CARE CAPITAL INC.
(FORMERLY RESINCO CAPITAL PARTNERS INC.)
MANAGEMENT'S DISCUSSION AND ANALYSIS – QUARTERLY HIGHLIGHTS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020**

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION (CONTINUED)

- The price of medical cannabis
- The lack of control over operations of the Company's investment operations;
- The fluctuations in the price of the Company's shares and the share price of the Company's investments;
- The Company's ongoing investment strategy; and
- The Company's ability to generate cash flow.

Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Accordingly, readers should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date of this MD&A – Quarterly Highlights and, other than as required by applicable securities laws, the Company assumes no obligation to update or revise them to reflect new events or circumstances.

ADDITIONAL INFORMATION

Additional information is available on SEDAR at www.sedar.com, or by contacting the Company's corporate office at Suite 810 – 789 West Pender Street, Vancouver, BC, Canada V6C 1H2, or by emailing the Company at asomjen@globalcarecapital.com.

RISK FACTORS

Risk is inherent in all business activities and cannot be entirely eliminated. Our goal is to enable the Company's business processes and opportunities by ensuring that the risks arising from our business activities, the markets and political environments in which we operate are mitigated. The risks and uncertainties described in the Annual MD&A are considered by management to be the most important in the context of the Company's business and are substantially unchanged as of the effective date of this MD&A – Quarterly Highlights. Those risks and uncertainties are not inclusive of all the risks and uncertainties the Company may be subject to and other risks may apply